Triathlon Medical Partners

Triathlon focuses on biomedical companies across three main sectors: medical devices, drug delivery platforms, and diagnostics. The firm targets companies that have developed a working prototype or have early clinical data and are preparing for regulatory submission or initial commercialization. Triathlon avoids biotech therapeutics and health IT software in favor of engineered products that require FDA clearance.

Yes, Triathlon typically leads or co-leads financing rounds in its portfolio companies. The firm often secures a board seat as part of its investment terms and works actively with management on regulatory strategy, clinical trial design, and commercial planning. This hands-on approach is a core part of its value proposition to both entrepreneurs and co-investors.

While Triathlon is headquartered in Cincinnati and emphasizes sourcing in the Midwest and Southeast, the firm invests nationally within the United States. Its geographic concentration in the Midwest reflects a strategic choice to operate in regions with high biomedical research output but lower venture competition compared to Boston or San Francisco.

Triathlon has historically pursued exits through strategic acquisitions by larger medical device or healthcare companies rather than through initial public offerings. Confirmed trade sales of portfolio companies include CardioMEMS to St. Jude Medical and OrthoHelix Surgical Devices to Tornier. The firm structures its fund lifecycle to prioritize these acquisition outcomes.

Investment decisions are led by Managing Partners Suzette Dutch and John Rice, who co-founded the firm in 2003. They draw on a network of clinical advisors from academic medical centers to support technical diligence, but the partnership itself maintains a flat decision-making structure without a large hierarchy.

Triathlon raises traditional closed-end venture capital funds with defined investment periods and fund lives. Its most recent publicly documented vehicle, Triathlon Medical Ventures III, closed in 2014 (per SEC filings). The firm has since continued investing under a subsequent fund series, consistent with standard institutional venture fund structures.

Triathlon does not invest in biotechnology therapeutics, health IT platforms, or general healthcare services. Its exclusive focus on engineered medical products — devices, diagnostics, and drug delivery systems — combined with its operational emphasis on FDA regulatory strategy, sets it apart from broad life sciences funds. The firm's Midwest base further shapes a deal flow network distinct from coastal venture clusters.